Skip to main content

Table 1 Characteristics of the BCAC European study participants

From: Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

Characteristics ER-negative patients who received chemotherapy Percent ER-negative patients who did not receive chemotherapy Percent ER-positive patients who received chemotherapy Percent
Number of patients 1499 100.00 835 100.00 3151 100.00
Age at diagnosis (mean ± SD, years) 51.69 ± 10.85 59.46 ± 12.18 51.74 ± 9.88
Family history       
 No 974 64.98 457 54.73 2233 70.87
 Yes 275 18.35 148 17.72 596 18.91
Missing 250 16.68 230 27.54 322 10.22
Tumor stage       
 1 356 23.75 401 48.02 606 19.23
 2 804 53.64 259 31.02 1751 55.57
 3 182 12.14 58 6.95 526 16.69
 Missing 157 10.47 117 14.01 268 8.51
Histological grade       
 Well-differentiated 23 1.53 97 11.62 390 12.38
 Moderately differentiated 293 19.55 310 37.13 1624 51.54
 Poorly/undifferentiated 1183 78.92 428 51.26 1137 36.08
Tumor size       
 ≤2 cm 664 44.30 528 63.23 1387 44.02
 ≥2 cm to ≤5 cm 744 49.63 271 32.46 1490 47.29
 ≥5 cm 91 6.07 36 4.31 274 8.70
Lymph node status       
 Negative 735 49.03 651 77.96 976 30.97
 Positive 764 50.97 184 22.04 2175 69.03
PR status       
 PR-negative 1271 84.79 633 75.81 546 17.33
 PR-negative HER2-negative 692 46.16 315 37.72 304 9.65
  1. Results are presented as number of patients unless stated otherwise. BCAC, Breast Cancer Association Consortium; ER, estrogen receptor; PR, progesterone receptor; SD, standard deviation; HER2, human epidermal growth factor receptor 2.